Clinical Trial Update: Cadonilimab Plus TACE in Patients With Intermediate-stage Unresectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for cadonilimab plus TACE in intermediate-stage unresectable hepatocellular carcinoma is reported, with status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Cadonilimab

Snippet

Sponsor: Eastern Hepatobiliary Surgery Hospital | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN